Market closed
Aerovate Therapeutics/$AVTE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aerovate Therapeutics
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.
Ticker
$AVTE
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
30
Website
AVTE Metrics
BasicAdvanced
$80M
-
-$2.44
0.99
-
Price and volume
Market cap
$80M
Beta
0.99
52-week high
$25.29
52-week low
$1.25
Average daily volume
148K
Financial strength
Current ratio
20.929
Quick ratio
20.539
Total debt to equity
0.546
Management effectiveness
Return on assets (TTM)
-44.88%
Return on equity (TTM)
-74.91%
Valuation
Price to book
1.04
Price to tangible book (TTM)
1.04
Price to free cash flow (TTM)
-1.104
Growth
Earnings per share change (TTM)
-15.06%
3-year earnings per share growth (CAGR)
9.22%
What the Analysts think about AVTE
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Aerovate Therapeutics stock.
AVTE Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AVTE Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AVTE News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Market closed
Upcoming events
Apr25
Aerovate Therapeutics
Dividend·Ex-dividend
Apr29
Aerovate Therapeutics
Dividend·Payment
$2.40
Per share
FAQs
What’s the current market cap for Aerovate Therapeutics stock?
Aerovate Therapeutics (AVTE) has a market cap of $80M as of April 22, 2025.
What is the P/E ratio for Aerovate Therapeutics stock?
The price to earnings (P/E) ratio for Aerovate Therapeutics (AVTE) stock is 0 as of April 22, 2025.
Does Aerovate Therapeutics stock pay dividends?
No, Aerovate Therapeutics (AVTE) stock does not pay dividends to its shareholders as of April 22, 2025.
When is the next Aerovate Therapeutics dividend payment date?
Aerovate Therapeutics (AVTE) stock does not pay dividends to its shareholders.
What is the beta indicator for Aerovate Therapeutics?
Aerovate Therapeutics (AVTE) has a beta rating of 0.99. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.